Protecting the littlest lungs

October 26, 2018 by Jennifer Rainey Marquez, Georgia State University
Credit: Carolyn Richardson

It's one of the most common respiratory infections in children, second only to the common cold. (By age three, just about every kid has been exposed at least once.) But for some young patients, respiratory syncytial virus, or RSV, can be highly dangerous, causing severe breathing problems and landing them in the hospital or worse.

According to the Centers for Disease Control and Prevention, every year in the U.S., RSV leads to more than 57,000 hospitalizations among children under age 5. A 2017 study found RSV infection is significantly associated with a higher risk of death than the seasonal flu, although the is most dangerous for and those with other chronic conditions or weakened immune systems. But even full-term, healthy babies can be at risk for hospitalization, and elderly people are also vulnerable.

Despite the potential severity of an infection, RSV has something else in common with your run-of-the- mill cold: There is no vaccine or effective treatment. Just one medication is approved to prevent severe illness in some high-risk patients, and it's extremely expensive and only sparingly applied.

"The younger the patient population, the more challenging development is, because the margin of safety must be so high," says Richard Plemper, professor in the Institute for Biomedical Sciences. "Yet the clinical need is huge."

Plemper is among those working to fill that need. He received a $2.2 million grant earlier this year from the National Institutes of Health's National Institute of Allergy and Infectious Diseases to develop effective, affordable therapies for RSV. He says designing a treatment for RSV or other RNA viruses is tricky because the genome of these viruses can change very rapidly in response to environmental conditions. This makes it easy for the virus to develop resistance to drugs.

"RNA reproduction is more error-prone than copying DNA, meaning mutations are often introduced during replication," Plemper says. "These errors are random, but if a mutation appears that happens to block the drug in any way, that genome will have a massive advantage and take over."

Combination therapies, or treatments that use more than one medication, can reduce the likelihood that drug-resistant strains will emerge, making them essential for clinical success. Plemper has developed a pair of compounds that can interrupt the virus's ability to replicate, and this funded project will determine whether the drug candidates are effective at treating the infection in mice, particularly when used in conjunction with one another.

Both compounds target an enzyme that makes copies of the virus's genetic template and is necessary for replication. Yet each targets the enzyme in a different way, meaning the medications could be used simultaneously.

One drug uses a modified version of substrates—the molecule upon which the enzyme acts—to essentially poison it. A second drug binds to the enzyme and presses a brake pedal on its activity.

"Now we want to know whether the drugs act synergistically—when we put them together, does it magnify the effectiveness?" Plemper says. "What we want is to create a superforce against RSV."

Explore further: Aviragen Therapeutics licenses Georgia State Technology to develop antiviral therapies

Related Stories

Aviragen Therapeutics licenses Georgia State Technology to develop antiviral therapies

July 5, 2016
The Georgia State University Research Foundation (GSURF) has entered into a licensing and sponsored research agreement with Aviragen Therapeutics, Inc., a Georgia-based pharmaceutical company developing the next generation ...

Flu virus could evolve resistance to pandemic drug: study

October 25, 2018
The influenza virus can evolve resistance to an anti-flu drug currently in development for use in pandemics but only if there are multiple genetic mutations, a study has found.

Flu's response to new drug explored

June 26, 2018
The new influenza drug Xofluza, developed by the Japanese pharmaceutical company Shionogi, was approved for clinical use in Japan in February 2018. Scientists from EMBL Grenoble have now investigated the drug's mode of action ...

Research pinpoints viral mutation that would trigger resistance to new anti-influenza drugs

April 25, 2018
Scientists at St. Jude Children's Research Hospital have identified a mutation that would enable the influenza virus to become resistant to a promising new class of drugs. The most advanced of these drugs are now in late ...

Researchers develop a new drug to combat the measles

April 16, 2014
A novel antiviral drug may protect people infected with the measles from getting sick and prevent them from spreading the virus to others, an international team of researchers says.

Recommended for you

Infants born to obese mothers risk developing liver disease, obesity

November 16, 2018
Infant gut microbes altered by their mother's obesity can cause inflammation and other major changes within the baby, increasing the risk of obesity and non-alcoholic fatty liver disease later in life, according to researchers ...

New study shows NKT cell subsets play a large role in the advancement of NAFLD

November 16, 2018
Since 2015 it has been known that the gut microbiota could have a direct impact on nonalcoholic fatty liver disease (NAFLD), which affects up to 12% of adults and is a leading cause of chronic liver disease. In the November ...

Antibiotic prescribing influenced by team dynamics within hospitals

November 15, 2018
Antibiotic prescribing by doctors is influenced by team dynamics and cultures within hospitals.

Discovery suggests new route to fight infection, disease

November 14, 2018
New research reveals how a single protein interferes with the immune system when exposed to the bacterium that causes Legionnaires' disease, findings that could have broad implications for development of medicines to fight ...

Zika may hijack mother-fetus immunity route

November 14, 2018
To cross the placenta, Zika virus may hijack the route by which acquired immunity is transferred from mother to fetus, new research suggests.

New research aims to help improve uptake of hepatitis C testing

November 14, 2018
New research published in Scientific Reports shows persisting fears about HIV infection may impact testing uptake for the hepatitis C Virus (HCV).


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.